Pediatric Gastroenterology

Standard of Care and Medical Management

At a Glance

Congenital tufting enteropathy is managed mainly with parenteral nutrition through a central line, carefully introduced feeds, and close monitoring for infection, liver disease, and loss of vein access; some children later need less or no PN, while others remain dependent.

The primary goal of treating Congenital Tufting Enteropathy (CTE) is to ensure your baby receives the hydration and calories they need to grow, despite their intestines being unable to absorb nutrients properly. While there is currently no “cure” that fixes the intestinal cells themselves, modern medical management allows many children with CTE to grow and live full lives ^[1]^[2].

The Core Treatment: Parenteral Nutrition (PN)

Because the small intestine cannot absorb enough nutrition, infants with CTE require Parenteral Nutrition (PN) ^[3]^[4]. This is a specialized liquid formula that contains protein, sugars, fats, vitamins, and minerals. It is delivered directly into the bloodstream through a central line (a thin tube placed in a large vein) ^[5]^[6]. Depending on the child, PN can be partial or total.

Growth and Development: In the early months, PN is essential for “catch-up growth,” allowing your baby to gain weight even while they are losing fluid through diarrhea ^[7]^[5].
Home Management: Once your baby is stable, most families learn to manage PN at home. This involves connecting and disconnecting the IV bags and caring for the central line site ^[1].
Declining Needs: As some children with CTE get older, their intestinal function may slightly improve, allowing them to reduce the number of hours they spend “on the pump” each day ^[1]^[8].

Supporting the Gut: Enteral Feeding

Even if the intestine cannot absorb enough to sustain the baby, doctors often recommend enteral feeding—giving small amounts of breast milk or formula by mouth or through a feeding tube ^[3]^[9].

Trophic Feeds: These tiny amounts are not meant for calories but to support mucosal function and oral skills ^[10].
Challenges: Some infants may struggle with even small feeds, showing signs like vomiting or a swollen belly (distension) ^[3]^[9]. Your team will advance these feeds using a highly individualized approach. Never adjust feed volumes, types, or routes independently without your team’s guidance ^[11]^[3].

Specialized Intestinal Rehabilitation

Managing CTE requires more than just a single doctor; it requires a multidisciplinary team. Many families find the best care at an Intestinal Rehabilitation Program ^[1]^[12]. These programs include:

Gastroenterologists who specialize in intestinal failure.
Registered Dietitians who fine-tune the PN recipe.
Specialized Nurses who focus on preserving the baby’s veins and preventing infections.
Pharmacists who manage the complex IV formulas.

This team approach has improved outcomes. In one small observational cohort of 13 patients managed by a specialized rehabilitation service, survival was reported at 92%, and half of the surviving children were eventually able to stop PN entirely as they grew ^[1]. However, these outcomes reflect a specific cohort, and many children remain PN-dependent for years or for life.

Managing Long-Term Risks

While PN is a life-saving tool, it comes with risks that your medical team will monitor closely:

Infection: Bacteria can travel through the central line into the bloodstream, causing sepsis. This is a major concern, and any fever must be treated as a medical emergency ^[13]^[14].
Liver Health: Long-term use of IV nutrition can stress the liver, a condition called PN-associated liver disease (PNALD) or Intestinal Failure-Associated Liver Disease (IFALD) ^[6]^[15]. Doctors may consider specific lipid (fat) blends for selected IFALD situations (like fish-oil-based emulsions) to help protect the liver ^[16]^[17].
Vein Preservation: Every central line requires a healthy vein. Protecting these “access sites” is a top priority for your surgical and nursing teams ^[6]^[18].

The Role of Intestinal Transplantation

An intestinal transplant is a complex decision evaluated at experienced transplant centers ^[13]^[1]. A transplant (which may involve isolated intestine or combined liver-intestine) may be considered if a child develops severe, irreversible liver disease, recurrent serious sepsis, or loses venous access ^[3]^[13]. The decision balances the risks of ongoing PN against the risks of lifelong immunosuppression and transplant complications ^[7].

Common questions in this guide

What is the main treatment for congenital tufting enteropathy?

The main treatment is parenteral nutrition, a liquid mixture of calories, protein, fats, vitamins, and minerals given directly into the bloodstream through a central line. It may provide all or only part of a child's nutrition while the intestine is unable to absorb enough.

Can parenteral nutrition for CTE be given at home?

Once a child is stable, many families are trained to give parenteral nutrition at home using an infusion pump and care for the central line. The care team teaches caregivers how to connect and disconnect the nutrition safely and how to watch for problems.

Why are small amounts of milk or formula sometimes given to a child with CTE?

Small feeds given by mouth or through a feeding tube may help support the intestinal lining and oral feeding skills, even when they do not provide enough calories. Vomiting or a swollen belly should be reported, and caregivers should not change the feed volume, type, or route without the medical team's guidance.

What complications need monitoring during long-term parenteral nutrition?

The main concerns are a bloodstream infection from the central line, liver disease related to intravenous nutrition, and loss of usable veins. Fever can signal a serious infection and requires urgent medical attention.

When might a child with CTE be evaluated for an intestinal transplant?

An intestinal transplant may be considered when a child develops severe, irreversible liver disease, repeated serious bloodstream infections, or loss of venous access. Experienced transplant centers weigh these risks against the risks of continuing parenteral nutrition and taking lifelong medicines to prevent rejection.

Can children with congenital tufting enteropathy eventually stop parenteral nutrition?

Some children's intestinal function improves with age, allowing them to spend fewer hours each day on the infusion pump or eventually stop parenteral nutrition. However, many children remain dependent on it for years or for life, so the outlook varies from child to child.

Get notified when new evidence is published on Congenital tufting enteropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Reversal of Intestinal Failure in Children With Tufting Enteropathy Supported With Parenteral Nutrition at Home.
Ashworth I, Wilson A, Aquilina S, et al.
Journal of pediatric gastroenterology and nutrition 2018; (66(6)):967-971 doi:10.1097/MPG.0000000000001894.
PMID: 29334565
2
Outcome associated with EPCAM founder mutation c.499dup in Qatar.
Hassan K, Sher G, Hamid E, et al.
European journal of medical genetics 2020; (63(10)):104023 doi:10.1016/j.ejmg.2020.104023.
PMID: 32735948
3
Tufting Enteropathy: A Review of Clinical and Histological Presentation, Etiology, Management, and Outcome.
Cai C, Chen Y, Chen X, Ji F
Gastroenterology research and practice 2020; (2020()):5608069 doi:10.1155/2020/5608069.
PMID: 33029133
4
Congenital Tufting Enteropathy: Biology, Pathogenesis and Mechanisms.
Das B, Sivagnanam M
Journal of clinical medicine 2020; (10(1)) doi:10.3390/jcm10010019.
PMID: 33374714
5
Approach to Congenital Diarrhea and Enteropathies (CODEs).
Kijmassuwan T, Balouch F
Indian journal of pediatrics 2024; (91(6)):598-605 doi:10.1007/s12098-023-04929-7.
PMID: 38105403
6
Poor Prognostic Factors in Patients with Parenteral Nutrition-Dependent Pediatric Intestinal Failure.
Choi SJ, Lee KJ, Choi JS, et al.
Pediatric gastroenterology, hepatology & nutrition 2016; (19(1)):44-53 doi:10.5223/pghn.2016.19.1.44.
PMID: 27066448
7
Case Series of Eight Congenital Tufting Enteropathy Patients and Literature Review.
Fang Y, Luo Y, Xu L, et al.
Clinical genetics 2025; (108(1)):69-74 doi:10.1111/cge.14702.
PMID: 39980129
8
Long-Term Follow-Up of Tufting Enteropathy Caused by EPCAM Mutation p.Asp253Asn and Absent EPCAM Expression.
Ozler O, Brunner-Véber A, Fatih P, et al.
JPGN reports 2021; (2(1)):e029 doi:10.1097/PG9.0000000000000029.
PMID: 37206930
9
[A Case of Congenital Tufting Enteropathy with EpCAM Gene Complex Heterozygous Mutation (c.491+1G>A; c.352_353ins CACC)].
Yang M, Xie YM, Zhang HY
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 2022; (53(3)):493-496 doi:10.12182/20220560109.
PMID: 35642160
10
Intestinal failure-associated liver disease in the neonatal ICU: what we know and where we're going.
Khalaf RT, Ford SL
Current opinion in pediatrics 2022; (34(2)):184-190 doi:10.1097/MOP.0000000000001105.
PMID: 35051980
11
A Rare Case of Neonatal-Onset Diarrhea Due to Congenital Tufting Enteropathy: Clinical, Histopathological, and Genetic Insights.
Rogalidou M, Dimakou K, Stefanaki K, et al.
Reports (MDPI) 2026; (9(3)) doi:10.3390/reports9030310.
PMID: 42784035
12
Tufting enteropathy: a rare anatomical cause of small bowel diarrhoea in infants with mild or no villous abnormality.
Das P, Malik R, Kaul S, Makharia GK
Gastroenterology and hepatology from bed to bench 2023; (16(2)):225-229 doi:10.22037/ghfbb.v16i1.2731.
PMID: 37554749
13
New mutations of EpCAM gene for tufting enteropathy in Saudi Arabia.
AlMahamed S, Hammo A
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 2017; (23(2)):123-126 doi:10.4103/1319-3767.203359.
PMID: 28361844
14
Risk factors for catheter-related bloodstream infections associated with home parental nutrition in children with intestinal failure: A prospective cohort study.
Puoti MG, D'Eusebio C, Littlechild H, et al.
Clinical nutrition (Edinburgh, Scotland) 2023; (42(11)):2241-2248 doi:10.1016/j.clnu.2023.09.007.
PMID: 37806076
15
Biopsy-Proven Intestinal Failure-Associated Liver Disease in Pediatric Short Bowel Syndrome: Histopathological Findings and Clinical Outcomes.
Karakoyun M, Barut D, Kunay B, et al.
Diagnostics (Basel, Switzerland) 2026; (16(14)) doi:10.3390/diagnostics16142205.
PMID: 42510069
16
Histopathological liver steatosis linked with high parenteral glucose and amino acid supply in infants with short bowel syndrome.
Gunnar R, Mutanen A, Merras-Salmio L, Pakarinen MP
JPEN. Journal of parenteral and enteral nutrition 2023; (47(1)):41-50 doi:10.1002/jpen.2416.
PMID: 35633305
17
Current strategies for managing intestinal failure-associated liver disease.
Secor JD, Yu L, Tsikis S, et al.
Expert opinion on drug safety 2021; (20(3)):307-320 doi:10.1080/14740338.2021.1867099.
PMID: 33356650
18
Surveillance practices of pediatric intestinal failure patients by North American intestinal rehabilitation programs.
Belza C, Courtney-Martin G, Avitzur Y, Wales PW
Intestinal Failure (New York, N.Y.) 2025; (7()):100323 doi:10.1016/j.intf.2025.100323.
PMID: 41646501

This page explains medical management for congenital tufting enteropathy for informational purposes only and does not constitute medical advice. Your baby's intestinal rehabilitation team should guide nutrition, central-line care, and transplant decisions.